• Fri frakt över 249 kr
  • •
  • Snabba leveranser
  • •
  • Billiga böcker
Kundservice

Du är på sajten för privatpersoner.

Företag, bibliotek eller offentlig verksamhet?

Du handlar på classic.bokus.com, där alla dina funktioner finns intakta.
Till classic.bokus.com
Bokus logotyp. Gå till startsidan.
  • Erbjudanden
  • Nyheter
  • Student
  • Topplistor
  • Barn & ungdom
  • Bokus Play
  • E-böcker
  • Pocketböcker
  • Spel & pussel

10% rabatt på allt med kod: NYSTART10 →

Sidfot

Mina sidor

    Hjälp

    • Kundservice
    • Vanliga frågor och svar
    • Frakt och leverans
    • Retur vid ångerrätt
    • Reklamera vara
    • Betalning
    • Köpvillkor
    • Allmänna villkor
    • Information om webbplatsens tillgänglighet

    Om Bokus

    • Om oss
    • Pressrum
    • För studenter
    • För företag
    • För bibliotek och offentlig verksamhet
    • För leverantörer
    • Hållbarhet

    Populärt

    • Aktuella erbjudanden
    • Presentkort
    • Studentlitteratur
    • Nya böcker
    • Topplistor
    • Signerade böcker
    • Engelska böcker

    Inspiration

    • Boktips
    • BookTok
    • Populära bokserier
    • Barnbokskaraktärer
    • Populära författare
    Logotyp för Bokus
    Följ oss på Facebook (extern länk)Följ oss på Instagram (extern länk)Följ oss på YouTube (extern länk)Följ oss på TikTok (extern länk)
    bokus @ CookiesAnpassa cookiesIntegritetspolicyKöpvillkor
    Till Citymail hemsida (extern länk)Till Budbee hemsida (extern länk)Till Postnord hemsida (extern länk)Till Schenker hemsida (extern länk)Till Early Bird hemsida (extern länk)Till Walleys hemsida (extern länk)
    1. Medicin
    2. Andra medicinska specialiteter
    3. Farmakologi

    Enzyme Inhibition in Drug Discovery and Development

    The Good and the Bad

    AvChuang Lu,Chuang Lu

    Inbunden, Engelska, 2010

    2 713 kr

    Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt över 249 kr.

    Beskrivning

    The science and applied approaches of enzyme inhibition in drug discovery and development Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the "good" inhibitions—desirable pharmacological effects—and "bad" inhibitions—drug–drug interactions and toxicity. The book discusses: The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug–drug interactions The inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway Through this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.

    Produktinformation

    • Utgivningsdatum:2010-01-26
    • Mått:163 x 243 x 45 mm
    • Vikt:1 311 g
    • Format:Inbunden
    • Språk:Engelska
    • Antal sidor:868
    • Förlag:John Wiley & Sons Inc
    • ISBN:9780470281741

    Utforska kategorier

    • Farmakologi inom Medicin
    • Kemi inom Naturvetenskap och teknik
    • Klinisk medicin och internmedicin inom Medicin

    Mer om författaren

    Chuang Lu, PhD, is the Associate Director in the Drug Safety and Disposition Department of Millennium Pharmaceuticals. His current research interests include drug-metabolizing enzymes, drug–drug interaction, and in vitro–in vivo correlation. Albert P. Li, PhD, is the President and CEO of In Vitro ADMET Laboratories, LLC and Advanced Pharmaceutical Sciences, Inc., and the cofounder, Chairman, and CSO of the ADMET Group. His experience spans over twenty-five years in the drug development industry, with over 150 publications. He is the editor of several books, including Drug–Drug Interactions in Pharmaceutical Development, published by Wiley.

    Recensioner i media

    "The description of each topic is clear, well organized and informative, making the book a useful or even essential high-level handbook." (ChemMedChem, November 2010)

    Innehållsförteckning

    • PREFACE. CONTRIBUTORS.PART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES.1. The Drug Discovery Process (Gerald T. Miwa).2. Medicinal Chemistry of the Optimization of Enzyme Inhibitors (Geraldine Harriman, Amy Elder, and Indranath Ghosh).3. Bioanalytical Technologies in Drug Discovery (Jing-Tao Wu).4. Safety Biomarkers in Drug Development: Emerging Trends and Implications (Eric R. Fedyk).5. The Role of Drug Metabolism in Drug Discovery (Tonika Bohnert and Liang-Shang Gan).6. Applied Pharmacokinetics in Drug Discovery and Development (Hua Yang, Xingrong Liu, Anjaneya Chimalakonda, Zheng Lu, Cuiping Chen, Frank Lee, and Wen Chyi Shyu).PART II. INHIBITION OF THE DRUG METABOLIZING ENZYMES—THE UNDESIRABLE INHIBITION.7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes (R. Scott Obach).8. Cytochrome P450 Induction (Edward L. LeCluyse, Michael W. Sinz, Nicola Hewitt, Stephen S. Ferguson, and Jasminder Sahi).9. Inhibition of Drug-Metabolizing Enzymes in Gastrointestinal Tract and Its Influence on the Drug–Drug Interaction Prediction (Aleksandra Galetin and J. Brian Houston).10. Enzyme Inhibition in Various In Vitro Systems (Ping Zhou).11. Cytochrome P450 Degradation and Its Clinical Relevance (Mingxiang Liao, Ping Kang, Bernard P. Murray, and Maria Almira Correia).12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition (Michael B. Fisher).13. Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes (Albert P. Li and Chuang Lu).14. Grapefruit Juice and Its Constituents as New Esterase Inhibitors (Suresh K. Balani).15. Transporter–Xenobiotic Interactions: An Important Aspect of Drug Development Studies (Gang Luo, Richard Ridgewell, and Thomas Guenthner).16. Polymorphisms of Drug Transporters and Their Clinical Implications (Cindy Q. Xia and Johnny J. Yang).17. Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation (Lisa L. von Moltke and David J. Greenblatt).18. Predicting Interindividual Variability of Metabolic Drug–Drug Interactions: Identifying the Causes and Accounting for Them Using Systems Approach (Amin Rostami-Hodjegan).PART III. INHIBITION OF THE DRUG TARGET ENZYMES—THE DESIRABLE INHIBITION.19. NF-κB: Mechanism, Tumor Biology, and Inhibitors (Lenny Dang).20. G-Protein-Coupled Receptors as Drug Targets (Wenyan Miao and Lijun Wu).21. Pharmacological Modulation of Ion Channels for the Treatment of Chronic Pain (Yi Liu and Ning Qin).22. Targeting the mTOR Pathway for Tumor Therapeutics (Wei Chen).23. HIV-1 Protease Inhibitors as Antiretroviral Agents (Sergei V. Gulnik, Elena Afonina, and Michael Eissenstat).INDEX.